Cholangiocarcinoma (CCA), a bile duct cancer, is an aggressive cancer with poor prognosis. It is typically recognized by its dense extracellular matrix nature which associated
Tag: RT
Molecularly Guided Drug Repurposing for Cholangiocarcinoma: An Integrative Bioinformatic Approach
Cholangiocarcinoma (CCA) has a complex immune microenvironment architecture, thus possessing challenges in its characterization and treatment. This study aimed to repurpose FDA-approved drugs for
In Silico Target Identification of Galangin, as an Herbal Flavonoid against Cholangiocarcinoma
Cholangiocarcinoma (CCA) is a heterogenous group of malignancies in the bile duct which proliferates aggressively. As a result, most patients are diagnosed in advanced
Analysis of laminins’ cognate receptors reveals the upregulation of ITGB4 in CCA tissues
Cholangiocarcinoma (CCA) is a rare but highly lethal cancer arising from biliary tract. Its incidence is highest in Northeast, Thailand (about 100
Molecularly Guided Drug Repurposing for Cholangiocarcinoma: An Integrative Bioinformatic Approach
Cholangiocarcinoma (CCA) has a complex immune microenvironment architecture, thus possessing challenges in its characterization and treatment. This study aimed to repurpose FDA-approved
Receptor-interacting protein kinase 1 is a key mediator in TLR3 ligand and Smac mimetic-induced cell death and suppresses TLR3 ligand-promoted invasion in cholangiocarcinoma
Cholangiocarcinoma (CCA) is a cancer of the bile duct with no effective therapy. This study explores the potential of inducing ‘apoptosis’ and
RTK25: A Comprehensive Molecular Profiling Strategy in Cholangiocarcinoma Using an Integrated Bioinformatics Approach
Cholangiocarcinoma (CCA) originates from the biliary tract. CCA is associated with a high mortality rate and a concerning increase in incidence. Tumour
Transcriptional Regulation of Cancer Immune Checkpoints: Emerging Strategies for Immunotherapy
The study of immune evasion has gained a well-deserved eminence in cancer research due to the development of immune checkpoint inhibitors, such
Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma
Cholangiocarcinoma (CCA) originates from the biliary tract. CCA is associated with a high mortality rate and a concerning increase in incidence. Here we
Key necroptotic proteins are required for Smac mimetic-mediated sensitization of cholangiocarcinoma cells to TNF-α and chemotherapeutic gemcitabine-induced necroptosis
Cholangiocarcinoma (CCA) is a lethal cancer of the bile duct and currently there is no effective therapy for this disease. This study